Johnson Michael Perkins 4

What Happened
Michael Perkins, Executive Vice President of IDEXX Laboratories (IDXX), received equity awards and converted/exercised derivative awards in mid‑February 2026. On Feb 12 he was granted several derivative awards (three awards totaling 4,139 units: 3,207; 162; and 770). On Feb 14 he exercised or converted 573 derivative shares (176, 179 and 218). To satisfy tax withholding obligations, 178 shares were delivered/sold at $629.35 per share (closing price per footnote) on Feb 14, generating $112,024.

Key Details

• Transactions reported: Grants (code A) on Feb 12: 3,207; 162; 770 derivative units (all $0.00 price). Exercises/conversions (code M) on Feb 14: 176; 179; 218 shares (listed at $0.00). Tax withholding (code F) on Feb 14: 178 shares disposed at $629.35 each for $112,024.
• Price reference: $629.35 is the issuer’s Nasdaq closing price on Feb 13, 2026 (footnote F2) used to value the tax‑withheld shares.
• Footnotes: include ESPP holdings (total 163.687 shares in the ESPP, see F1) and several vesting schedules for options and RSUs (F3–F8 describe multi‑year vesting).
• Shares owned after the transactions: not specified in the provided excerpts of the filing.
• Timeliness: filing date is Feb 17, 2026 (period of report Feb 12, 2026). The provided data does not mark the filing as late.

Context

• Many lines are derivative transactions: grants (A) reflect awards/RSUs or options granted; exercise/conversion lines (M) reflect converting vested derivatives into shares. The F code line shows shares surrendered/sold to cover tax withholding — a common internal disposal following an exercise or vesting.
• These are routine corporate compensation events (awards and tax withholding) rather than an open‑market purchase or discretionary sale; such withholding sales do not necessarily indicate the insider’s view of the stock.